Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness of subcutaneous immunotherapy in adults with allergic rhinitis
NL-OMON25681Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2009
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of five-grass-pollen extract in allergic rhinitis (AR) (2 arms), sponsored by Erasmus MC. Primary endpoints: Cost per successfully treated patient and Mean daily total nasal symptom score in multi-sensitized patients after one year. Started Oct 2009; status: active, not recruiting.
02
Drugs
five-grass-pollen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NL-OMON25681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25681.